Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPISTRY Phase II Platform Trial
NCT04589845Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2021
- Primary completion
- Sep 2032
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 2 trial of entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine in solid tumor, sponsored by Roche. Started Jan 2021; status: active, not recruiting.
02
Drugs
entrectinibalectinibatezolizumabipatasertibtrastuzumab emtansine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04589845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589845.